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ABSTRACT
Objective Primary sclerosing cholangitis (PSC) is a
chronic cholestatic liver disease often leading to end-
stage liver disease. Its pathogenesis remains largely
unknown, although frequent concomitant IBD hints
towards common factors underlying gut and bile duct
inﬂammation. Considering the mounting evidence on the
involvement of the intestinal microbiota in initiating and
determining IBD phenotype, we investigated intestinal
microbiota composition in patients with PSC.
Design Stool samples were collected from 147
individuals (52 patients with PSC, 52 age, gender and
body mass index-matched healthy volunteers, 13 UC and
30 patients with Crohn’s disease). An independent
validation cohort of 14 PSC and 14 matched controls
was recruited. 16S rDNA sequencing of faecal DNA was
performed (Illumina MiSeq).
Results The microbiota of patients with PSC was
characterised by decreased microbiota diversity, and a
signiﬁcant overrepresentation of Enterococcus ( p=3.76e-
05), Fusobacterium (p=3.76e-05) and Lactobacillus
(p=0.0002) genera. This dysbiosis was present in
patients with PSC with and without concomitant IBD
and was distinct from IBD, and independent of
treatment with ursodeoxycholic acid. A decision tree
based on abundances of these three genera allowed
reliable classiﬁcation in the validation cohort. In
particular, one operational taxonomic unit belonging to
the Enterococcus genus was associated with increased
levels of serum alkaline phosphatase (p=0.048), a
marker of disease severity.
Conclusions We here present the ﬁrst report of
PSC-associated faecal dysbiosis, independent from IBD
signatures, suggesting the intestinal microbiota could be
a contributing factor in PSC pathogenesis. Further
studies are needed to conﬁrm these ﬁndings and assess
causality.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic
cholestatic liver disease characterised by the devel-
opment of multifocal bile duct strictures that can
lead to liver ﬁbrosis and subsequent cirrhosis.1 PSC
has an incidence of 1.3 per 100 000 individuals.
There is no effective medical treatment for this
condition and liver transplantation is offered to
patients with PSC with end-stage liver disease,
although PSC recurrence occurs in up to 23% of
patients after liver transplantation.2
The pathogenesis of PSC remains poorly under-
stood, with current evidence suggesting that
genetic, immunologic and environmental factors all
play a role. Between 60% and 80% of patients with
PSC have concomitant IBD, most frequently ulcera-
tive colitis (UC), suggesting that inﬂammation in
the colon is of importance in disease presentation.
The intestinal microbiota has also been suggested
to play a role in PSC pathogenesis, as translocated
bacterial products are more frequently found in
explant livers from patients with PSC when com-
pared with patients with other liver disorders.3
Metronidazole therapy, which alters bacterial
microbiota composition, transiently improves liver
function tests without however altering transplant
free survival.4 Furthermore, colectomy performed
before liver transplantation decreases PSC relapse
rate after liver transplantation, indicating that the
Signiﬁcance of this study
What is already known on this subject?
▸ Primary sclerosing cholangitis is a cholestatic
liver disease strongly associated with IBD.
▸ Intestinal microbiota play an important role in
the pathogenesis of IBD.
▸ Antibiotic therapy in patients with primary
sclerosing cholangitis transiently improves liver
function tests without however altering
transplant free survival.
What are the new ﬁndings?
▸ Primary sclerosing cholangitis is associated
with alterations in intestinal microbiota,
independently of comorbidity with IBD.
▸ Three genera Enterococcus, Lactobacillus and
Fusobacterium are overrepresented in patients
with primary sclerosing cholangitis.
▸ An operational taxonomic unit belonging to the
Enterococcus genus is positively correlated with
the levels of alkaline phosphatase.
How might it impact on clinical practice in
the foreseeable future?
▸ Intestinal microbiota modulation through diet,
faecal microbiota transplantation, antibiotics or
probiotics may be used in the treatment or
prevention of primary sclerosing cholangitis.
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colon is instrumental in the initiation of inﬂammation in the
liver.2 Moreover, a new antigen-dependent mouse model con-
ﬁrmed that immune-mediated cholangitis is caused by T cells
primed in the gut-associated lymphoid tissue which further sup-
ports the hypothesis that cholangitis is gut triggered and immune
mediated.5 More recently, a Mdr2(−/−) mouse model of PSC
was developed, leading to a more severe phenotype of PSC when
raised in germ-free conditions, further suggesting a role of the
intestinal microbiota in the development of bile duct injury.6
The role of the intestinal microbiota in the pathogenesis of
IBD is well recognised. Bacteria inﬂuence intestinal inﬂamma-
tion through the interplay with the immune system, such as the
induction of CD25+ regulatory T cells, downregulation of
proinﬂammatory and upregulation of anti-inﬂammatory cyto-
kines.7 Dysbiosis, the deviation from the normal composition of
the human intestinal microbiota, has already been described in
IBD. Crohn’s disease (CD) dysbiosis is mainly characterised by
reduced microbial richness,7 a decrease in Faecalibacterium
prausnitzii,8 Biﬁdobacterium adolescentis, Dialister invisus and
uncharacterised species of Clostridium cluster XIVa and an
increase in the mucus-degrading Ruminococcus gnavus.9 On the
other hand, patients with UC display normal intestinal microbial
richness10 and UC dysbiosis is characterised by a reduction in
Roseburia hominis and F. prausnitzii, both producers of butyr-
ate, a short-chain fatty acid with known anti-inﬂammatory
properties.7 11
Considering the already described IBD-associated dysbiosis
and the frequent concomitant development of IBD with PSC,
we hypothesised that the intestinal microbiota might be altered
in patients with PSC. We analysed the composition of the micro-
biota in a well-characterised cohort of patients with PSC and
compared them to healthy controls and patients with IBD.
METHODS
Patients
Patients with PSC, IBD and PSC with concomitant IBD were
included. All patients were recruited at the IBD or liver out-
patient clinic of the University Hospitals of Leuven (Belgium).
PSC diagnosis followed established guidelines and was based
on symptoms and/or signs of chronic cholestatic liver injury,
negative anti-mitochondrial autoantibodies and HIV serology,
imaging compatible with bile duct injury (magnetic resonance
cholangiopancreatography, endoscopic retrograde cholangiopan-
creatography) and/or liver biopsy with typical ﬁndings in the
absence of drug use associated with cholestatic liver injury.12
The diagnosis of liver cirrhosis was established on biopsy or by
imaging with MRI or elastography in conjugation with labora-
tory and clinical ﬁndings supporting the diagnosis of cirrhosis
(see online supplementary table S1).
Diagnosis of CD or UC was conﬁrmed by a combination of
endoscopy, histopathology and radiological and biochemical
investigations, according to existing guidelines.13 14
Healthy controls were selected from the Flemish Gut Flora
Project (FGFP) currently including over 3000 sampled volun-
teers, to match patients with PSC for age, gender and body
mass index (BMI).
All patients and healthy controls signed informed consent
before sample collection. The local ethical committee approved
the study (reference number: S53684 and S58125).
Clinical data
Basic demographic data, clinical data and information about
possible confounders of microbiota analysis (eg, speciﬁc diet,
prebiotic and probiotic use, antibiotic treatment in the last
30 days) were collected at the time of inclusion for all patients.
Also, complementary clinical information was extracted from
the clinical ﬁles of the patients. Harvey–Bradshaw index (HBI)
and partial Mayo score were collected from patients with CD
and UC, respectively. Table 1 summarises study subjects
characteristics.
Clinical information from the healthy controls was extracted
from the FGFP database, which contains a medical report from
the general practitioner and self-reported information about
possible confounders for intestinal microbiota analysis (eg, pre-
biotic and probiotic use).
Samples and DNA extraction
Fresh faecal samples from patients were collected at the out-
patient clinic of the University Hospitals of Leuven and frozen
at −80°C within 12 h after sampling. Blood samples were taken
during the same clinic visit.
The faecal samples of the healthy controls were collected by
the volunteers and immediately frozen at −20°C in their home
freezers. They were transported frozen within a week to the
laboratory and stored at −80°C.
Faecal calprotectin measurements were performed for all
patients with the fCAL ELISA kit (Bühlmann, Schönenbuch,
Switzerland). Faecal calprotectin was not quantiﬁed in healthy
controls and in patients with UC because samples were frozen
on collection, which may result in overestimation, as stated by
the manufacturer.
Bacterial DNA extraction from faecal samples was performed
with the MOBIO PowerMicrobiome RNA isolation kit (MO
BIO Laboratories, Carlsbad, California, USA), using an adapted
protocol. In short, after mechanical and chemical lysis in Glass
Bead Tubes, samples were incubated at 90°C for 10 min.
Afterwards, normal protocol was followed with the exclusion of
the DNase I step at the end.
Quantiﬁcation of bacterial DNA for PCR was done with a
Qubit 2.0 ﬂuorometer (Life Technologies Grand Island,
New York, USA). After PCR ampliﬁcation, quality control and
quantiﬁcation of the libraries was performed with Fragment
Analyzer (Advanced Analytical Technologies, Ames, Iowa, USA).
Sequencing 16S rRNA gene
The V4 region of the 16S rRNA gene was ampliﬁed with
primer pairs 515F and 806R, with single multiplex identiﬁer
and adaptors as described by Kozich et al.15 Sequencing was
performed on Illumina MiSeq sequencer (MiSeq V.2 kit,
Illumina, San Diego, California, USA) yielding 250 bp
paired-end reads. After demultiplexing, paired-end reads were
merged using FLASH software V.1.2.10 ( Johns Hopkins
University, Baltimore, USA)16 with default parameters.
Combined reads quality threshold was set at minimum 30
quality score over 90% of read length (Fastx tool kit; http://
hannonlab.cshl.edu/fastx_toolkit/) and chimeric sequences were
ﬁltered out (UCHIME17).
Microbiota analysis
Each sample was downsized to 10 000 reads by random selec-
tion of quality-checked reads. Genus and phylum abundance
matrices were obtained by mapping to the Ribosomal Database
Project (RDP) reference database (RDP classiﬁer18). The oper-
ational taxonomic unit (OTU)-level abundance matrix was
obtained by de novo clustering of reads at 97% identity, corre-
sponding to species-level clustering (USEARCH19). For speciﬁc
OTU taxonomic assignment, we performed a megaBLAST
search of the OTU centroid read against NCBI 16S rDNA
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sequences. The oligotyping pipeline20 was used for identiﬁca-
tion of different oligotypes in the genera of interest.
Statistical analysis
Statistical analyses were performed in R (V.3.1.3), using the phy-
loseq21 and vegan( J Oksanen, FG Blanchet, R Kindt, et al.
vegan: Community Ecology Package. R package version 2.3–0,
2015) packages. Continuous variables were tested for normality
with the Shapiro–Wilk test. Non-parametric test were applied to
analyse microbiome data, with multiple testing correction when-
ever applicable (adjustment for false discovery rate (FDR)).
Adjusted p values <0.05 were considered signiﬁcant.
Mann–Whitney U (Kruskal–Wallis for more than two groups)
was used to test median differences in α-diversity (microbiota
species richness) and genera abundances between different
groups. Correlation between genera abundances and continuous
metadata was performed with Spearman correlation. Principal
coordinates analysis (PCoA) on OTU-level community compos-
ition (metric: Bray–Curtis dissimilarity) was used to visualise
microbiota variation across samples and signiﬁcance of commu-
nity differences between groups of patients were tested with
Adonis non-parametric test.
Multivariate Association with Linear Models package
(MaAsLin R V.0.0.3) was used for deconfounded multivariate
assessment of associations between taxa abundances and meta-
data, using default parameters.22
Weka (V.3.6.12, University of Waikato) was used for training
(ﬁrst cohort) and testing (validation cohort) a J48 decision tree
classiﬁer for the microbiota signature discriminating PSC from
healthy controls.23 The model’s performance in terms of accur-
acy of prediction was evaluated by the area under the receiver
operating characteristic curve (AUC) on the test set (validation
cohort).
RESULTS
Demographic data
Cohort 1 included 52 patients with PSC (see online supplemen-
tary ﬁgure S1): 13 had PSC without IBD (hereafter referred to as
PSC only). As control groups, 52 age, gender and BMI-matched
healthy controls were selected from the FGFP database and 43
additional patients with IBD without PSC were recruited.
A validation cohort of 14 patients with PSC (of whom 9 with
concomitant IBD) was recruited as an independent test set.
Additionally, 14 age, gender and BMI-matched healthy controls
were selected from the FGFP database for the independent test
set. These subjects were recruited and sampled after the initial
analysis and faecal DNA was extracted and sequenced in an
independent run. Patient characteristics from both cohorts are
summarised in table 1.
The majority of patients with IBD were in remission, as evi-
denced by low clinical activity scores (HBI and partial Mayo
score) and normal C-reactive protein (CRP) levels.
Faecal dysbiosis in patients with PSC includes decreased
species richness and altered community composition,
regardless of concomitant IBD and UDCA treatment
The overall faecal microbiota composition of patients (PSC, CD
or UC) was signiﬁcantly different from that of healthy controls,
as evidenced by their separation along the ﬁrst axis of the PCoA
(on OTU-level abundance matrix with the Bray–Curtis dissimi-
larity; ﬁgure 1A; Adonis R2=0.1, p value=0.00099). Focusing
on the patients with PSC, samples from the different subgroups
(PSC only, PSC-UC and PSC-CD) were not signiﬁcantly different
from one another, such that they cluster together on the PCoA
(Adonis p values>0.05; see online supplementary table S2).
However, they did cluster apart from patients with CD and UC
(Adonis R2=0.0932, p value=0.001; ﬁgure 1A). Of note, the
microbiota of patients with PSC under ursodeoxycholic acid
(UDCA) treatment was not signiﬁcantly different from patients
with PSC without UDCA treatment (see online supplementary
table S2). Also, the microbiota of patients with PSC treated who
underwent antibiotic treatment in the past month was not sig-
niﬁcantly different from that of patients with PSC with no anti-
biotic treatment.
We next set to characterise PSC dysbiosis, starting with global
alterations in microbiota richness. The species richness, deﬁned
Table 1 Study subjects characteristics from both cohorts (n=175)
Patient characteristics
PSC only
(n=18)
PSC-UC
(n=27)
PSC-CD
(n=21) UC (n=13) CD (n=30)
Healthy controls
(n=66)
Male (%) 10 (55.6) 20 (74) 18 (85.7) 4 (30.8) 15 (50) 49 (74)
Median (IQR) age (years) 49 (15.25) 43 (14) 49 (17) 50 (28) 52 (14.25) 51.5 (17)
Median (IQR) BMI (kg/m²) 23.45 (8.25) 23.7 (6.2) 23.5 (5.2) 25.6 (4.9) 25.25 (5.4) 23.72 (4.9)
Current smoker (%) 1 (5.6) 1 (3.7) 7 (33.3) 2 (15.4) 11 (36.7) 4 (7.7)
Median (IQR) age (years) at diagnosis of PSC 37.5 (15) 32 (8.5) 35 (21) NA NA NA
Liver transplantation (%) 7 (38.9) 7 (25.9) 1 (4.8) 0 (0) 0 (0) 0 (0)
Cirrhosis (%) 1 (5.6) 7 (25.9) 5 (23.8) 0 (0) 0 (0) 0 (0)
Pouch (%) 0 (0) 4 (14.8) 0 (0) 0 (0) 0 (0) 0 (0)
Calprotectin (mg/g)—median (IQR) 100 (226.1) 121 (406) 339 (1081.95) NA 132.5 (214.25) NA
CRP (mg/L)- median (IQR) 1.4 (3.6) 2.25 (3.975) 2.05 (7.15) 2.2 (3.8) 2.1 (2.7) 0.7 (1.3)
IBD activity score—median (IQR) NA 0 (2) 1 (4.25) 2 (3) 3 (4) NA
Medications
UDCA (%) 13 (72.2) 18 (66.7) 16 (76.2) 0 (0) 1 (3.3) 0 (0)
5-Amminosalicylates (%) 0 (0) 18 (66.7) 4 (19) 12 (92.3) 2 (6.7) 0 (0)
Corticosteroids (%) 3 (16.7) 3 (11.1) 2 (9.5) 3 (23) 1 (3.3) 0 (0)
Immunosuppression (%) 8 (44.4) 7 (25.9) 4 (19) 4 (30.8) 8 (26.7) 0 (0)
Anti-TNF α (%) 0 (0) 5 (18.5) 8 (38) 3 (23) 16 (53.3) 0 (0)
Antibiotics in the last month (%) 2 (11.8) 4 (16.7) 5 (26.3) 0 (0) 0 (0) 0 (0)
Probiotics in the last month (%) 1 (6.7) 3 (13) 3 (18.7) 0 (0) 5 (20,8) 2 (3)
BMI, body mass index; CD, Crohn’s disease; PSC, primary sclerosing cholangitis; UC, ulcerative colitis; UDCA, ursodeoxycholic acid.
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as the number of different OTUs observed in the sample, was
decreased in patients with PSC compared with healthy controls
(p value=0.026; ﬁgure 1B). Although this trend was observed
in all subgroups of PSC, decreased richness was only signiﬁ-
cantly lower in PSC-UC compared with healthy controls after
splitting the subgroups and multiple testing correction
(FDR-adjusted p value=0.019). We also conﬁrmed both the pre-
viously reported decreased microbiota richness in patients with
CD compared with healthy controls (FDR-adjusted p
value=0.0185) and the absence of reduced richness in patients
with UC compared with healthy controls.
Three genera, including Enterococcus, are increased in
patients with PSC regardless of concomitant IBD and UDCA
treatment
Both at phylum-level (ﬁgure 2A) and genus-level (ﬁgure 2B)
composition, signiﬁcant differences were observed between PSC
and healthy controls. At the phylum level, Bacteroidetes were
more abundant in patients with PSC, whereas Firmicutes were
underrepresented (FDR-adjusted p value=2.097e-03 and
1.636e-06, respectively). Healthy controls had lower abundance
of Fusobacteria than patients with PSC (FDR-adjusted
p value=1.23e-12).
At the genus level, when compared with healthy controls,
patients with PSC only displayed increased abundance of
Enterococcus, Fusobacterium, Lactobacillus, Morganella and
Streptococcus and decreased abundance of Anaerostipes
(FDR-adjusted p values=3.76e-05, 3.76e-05, 0.0002, 0.007,
0.046 and 0.046, respectively) (ﬁgure 3A). The same signal was
found for Enterococcus, Fusobacterium, Lactobacillus and
Streptococcus when comparing PSC-UC or PSC-CD with
healthy controls (see online supplementary Table S3). There
were four genera signiﬁcantly altered in all the PSC subgroups
as compared with healthy controls—Enterococcus,
Streptococcus, Lactobacillus and Fusobacterium, all but the
latter exclusively associated with PSC dysbiosis, and not with
UC nor CD dysbiosis (ﬁgure 3B). The three bacterial genera
remained signiﬁcantly different between PSC and healthy con-
trols after excluding patients taking UDCA. Most of these
changes remained signiﬁcant after excluding patients with cir-
rhosis or liver transplantation from the analysis (see online sup-
plementary table S4). After excluding patients with antibiotic
use, Streptococcus was no longer signiﬁcantly different between
patients with PSC only and healthy controls.
The three genera microbiota signature discriminates
patients with PSC from healthy controls
Eliminating genera with confounding association to IBD
(without concomitant PSC) or antibiotic treatment, the micro-
bial signature of PSC described above is composed of three
genera: Enterococcus, Lactobacillus and Fusobacterium. All
these genera are speciﬁcally overrepresented in all subgroups of
patients with PSC, after excluding potential confounders (anti-
biotic treatment, probiotics, treatment with UDCA, liver cirrho-
sis and liver transplantation). We explored to what extent the
observed signature could be used to correctly discriminate PSC
samples. We thus used the data from the ﬁrst cohort to train a
J48 decision tree classiﬁer to predict PSC versus healthy con-
trols diagnosis, based on the abundances of the three
PSC-associated genera (see online supplementary ﬁgure S2).
The trained model yielded a correct classiﬁcation of 95% of the
subjects. Testing this model in the validation cohort, which was
Figure 1 Faecal microbiota variation across healthy controls (HC) and patients with primary sclerosing cholangitis (PSC) and IBD (n=147). (A)
Variation in microbial community composition represented in a principal coordinates analysis (PCoA) of the Bray–Curtis dissimilarity matrix,
calculated from the operational taxonomic unit (OTU)-level abundance matrix. Patients with HC, PSC and IBD are signiﬁcantly different (see online
supplementary table S2), while PSC subgroups are not. (B) Box plots representation of microbiota richness (number of observed OTUs per sample)
distribution across HC, PSC (PSC only, PSC-ulcerative colitis (UC) and PSC-Crohn’s disease (CD)) and IBD (UC and CD). HC have signiﬁcantly higher
species richness than all patients with PSC combined, and than PSC-UC and CD individually. Horizontal bars represent false discovery rate
(FDR)-corrected p value <0.05 (Kruskal–Wallis rank sum test). The body of the box plot represents the ﬁrst and third quartiles of the distribution,
and the median. The whiskers extend from the quartiles to the last datapoint within 1.5× IQR, with outliers beyond represented as dots.
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independently recruited, sampled and sequenced, yielded a
correct classiﬁcation of 71% of the subjects with an acceptable
discrimination (AUC=0.724).
The microbiota signature of PSC is conserved across PSC
severity groups, even after controlling for clinical
confounders
We then assessed associations between the abundances of genera
included in the PSC signature described above and disease sever-
ity, both for PSC and IBD. For this purpose, patients with PSC
were divided according to disease severity into stable patients,
patients with cirrhosis and patients having undergone liver
transplantation. Patients with IBD were divided into patients in
clinical remission (HBI<4 for CD and partial Mayo<3 for UC),
patients with active disease and patients with total colectomy
and ileoanal pouch.
We ﬁrst tested for genera signiﬁcantly associated with PSC
disease severity, while removing the inﬂuence of possible con-
founders, by performing a multivariate analysis (MaAsLin). Sex,
age, BMI, smoking status, antibiotic use and UDCA treatment
were used as potential clinical confounders. Besides conﬁrming
previously reported associations such as the increase in
Methanobrevibacter abundance with age, we conﬁrmed that the
genera Fusobacterium, Enterococcus and Lactobacillus were sig-
niﬁcantly decreased in healthy controls compared with all
patients with PSC, regardless of disease severity, even when
deconfounding for the six other variables (p value <0.001; see
online supplementary table S5).
Enterococcus abundance correlates to alkaline phosphatase
levels, but this is not conﬁrmed by multivariate analysis
Interestingly, the alterations in the signature genera abundances
were more pronounced in patients with cirrhosis and liver trans-
plantation in comparison with patients having stable disease (see
online supplementary ﬁgure S3A), although these lacked statis-
tical signiﬁcance, probably due to the reduced sample size after
splitting the groups. The same ﬁndings were observed in
patients with IBD, where the differences at the genus level were
more pronounced in patients with active disease or patients
with an ileoanal pouch than in patients in clinical remission (see
online supplementary ﬁgure S3b). Again, these differences were
not signiﬁcant after correction for multiple testing.
Figure 2 Faecal microbiota
composition in healthy controls,
patients with primary sclerosing
cholangitis (PSC) (PSC-only,
PSC-ulcerative colitis (UC) and
PSC-Crohn’s disease (CD)) and IBD (UC
and CD) (n=147). (A) Phylum-level
median relative abundances and (B)
genus-level median relative
abundances. The top 14 more
abundant genera are represented and
all others are summed into the
category ‘others’.
Sabino J, et al. Gut 2016;65:1681–1689. doi:10.1136/gutjnl-2015-311004 1685
Gut microbiota
group.bmj.com on October 9, 2016 - Published by http://gut.bmj.com/Downloaded from 
Since disease severity groups provided hints of a possible
association between severity and the amplitude of the micro-
biota signature, we next evaluated the correlation between the
three PSC-associated genera and serum γ-glutamyl transpepti-
dase (GGT) and alkaline phosphatase (ALP), two clinical
markers of cholestasis. In fact, a persistent elevation of ALP
often triggers the diagnosis of PSC. A signiﬁcant positive spear-
man correlation was found between the abundance of
Enterococcus, and Lactobacillus and GGT (see online supple-
mentary table S6). Notably, we found a positive correlation
(Spearman ρ=0.29, adjusted p value=0.012199; ﬁgure 4)
between Enterococcus abundance and ALP, although this correl-
ation did not withstand multivariate analysis deconfounding for
sex, age, BMI, smoking status and antibiotic use (adjusted
p value=0.6).
We also examined the genus Enterococcus at OTU (roughly
comparable to species) level. There were three OTUs assigned
to the genus Enterococcus, one of which (OTU1) was signiﬁ-
cantly different in all subgroups of patients with PSC compared
with healthy controls, while showing no signiﬁcant difference
between patients with IBD (without PSC) and healthy controls.
Furthermore, the association between OTU1 and PSC diagnosis
is signiﬁcant regardless of disease severity (stable, cirrhosis and
liver transplantation), even when deconfounding for sex, age,
faecal calprotectin, BMI, smoking, UDCA use, serum ALP
levels, antibiotic use and liver transplantation. Comparably to
the genus-level analysis, OTU1 was also positively correlated
with GGT, ALP and ALT (Spearman ρ=0.321, 0.258, 0.296,
adjusted p value=0.001, 0.048, 0.002, respectively), but could
not be conﬁrmed in multivariate analysis. The centroid read of
Figure 3 Genus-level microbiota
signature of primary sclerosing
cholangitis (PSC) (n=147). (A) Venn
diagram summarising the overlap
between the lists of genera with
signiﬁcantly different abundances in
patient groups compared with healthy
controls (HC). Genera overrepresented
in patients as compared with controls
are in red, and underrepresented ones
in blue. The lists of genera included in
each of the Venn diagram’s sets
(labelled from A to M) can be found in
online supplementary table S3. (B) Box
plots showing abundances of
Fusobacterium, Enterococcus,
Lactobacillus and Streptococcus in HC,
patients with PSC and IBD. These
compose the PSC signature (ie, genera
signiﬁcantly overrepresented or
underrepresented in all PSC subgroups
compared with HC), with the exception
of Streptococcus, which association
falls below signiﬁcance after excluding
patients under antibiotic treatment.
Horizontal bar represents false
discovery rate (FDR)-corrected p value
<0.05 (Mann–Whitney test). Box plot
deﬁnition is provided in the legend of
ﬁgure 1.
Figure 4 Positive correlation between Enterococcus abundance and
alkaline phosphatase (ALP), a clinical marker for cholestasis and
primary sclerosing cholangitis (PSC) progression (n=87, Spearman
ρ=0.29, adjusted p value=0.012199). Black dots correspond to patients
with PSC without cirrhosis or liver transplantation. Grey dots
correspond to patients with PSC with either cirrhosis or liver
transplantation.
1686 Sabino J, et al. Gut 2016;65:1681–1689. doi:10.1136/gutjnl-2015-311004
Gut microbiota
group.bmj.com on October 9, 2016 - Published by http://gut.bmj.com/Downloaded from 
OTU1 had equally high similarity, but below perfect, matches to
the species Enterococcus hirae, E. faecium and E. faecalis (see
online supplementary table S7). The other two OTUs (OTU2
and OTU3) did not have much impact in the overall results.
The three genera were also decomposed by oligotyping ana-
lysis to determine whether a speciﬁc oligotype associated with
PSC severity. The Enterococcus, Fusobacterium and
Lactobacillus genus decomposed in 2, 3 and 13 olygotypes,
respectively. One oligotype (OLIG2; see online supplementary
ﬁgure S4) from the Enterococcus genus was positively correlated
with serum ALP levels (Spearman ρ=0.34, adjusted p
value=0.0452). The other oligotype also correlated positively
with ALP serum level, but did not resist multiple testing correc-
tion (Spearman r=0.32, non-adjusted p value=0.0332).
DISCUSSION
In the present study, we analysed the faecal microbiota asso-
ciated with PSC. Because patients with PSC frequently develop
concomitant IBD, we assembled a large cohort of patients with
PSC, and compared their microbiota with two control groups,
one being patients with IBD without PSC and the other age,
gender and BMI-matched healthy volunteers. To conﬁrm our
ﬁndings, a second smaller validation cohort of patients with
PSC and healthy controls was independently recruited, sampled
and sequenced. We show that the faecal microbiota in patients
with PSC is signiﬁcantly different from that of healthy volun-
teers and patients with IBD. Furthermore, samples from patients
with both PSC and concomitant IBD clustered together with
PSC only and apart from patients with IBD without PSC.
Therefore, PSC seems to shape the microbiota composition
stronger than IBD, allowing for a clear separation of samples of
patients with PSC according to PSC diagnosis and regardless of
concomitant IBD.
PSC dysbiosis was characterised by reduced microbiota
diversity. We also found a consistent signature of four genera—
Enterococcus, Fusobacterium, Lactobacillus and Streptococcus—
which were overrepresented in all subgroups of PSC (PSC only,
PSC-UC and PSC-CD) compared with healthy controls. After
taking into account antibiotic use, Streptococcus was no longer
signiﬁcantly overrepresented in patients with PSC. The same
three genera (Enterococcus, Fusobacterium and Lactobacillus)
signature was found when restricting to patients without liver
cirrhosis, liver transplantation or associated IBD. We conﬁrmed
this signature with multivariate analysis, correcting for possible
clinical confounders. This signature allowed discrimination of
patients with PSC from healthy controls in the validation cohort
with 71% accuracy.
Interestingly, the three genera forming the PSC signature have
already been associated with other diseases. Enterococcus and
Lactobacillus have been associated with dysbiosis in liver cirrho-
sis24 25 and IBD.26 These genera represent lactic acid-producing
bacteria, with the former encoding a wide range of both intrin-
sic and acquired resistance to antibiotics.27 Fusobacterium has
also been previously associated with liver cirrhosis,24 IBD26 28
and colorectal cancer.29
It is worth mentioning that a recent study analysed the
mucosa-associated microbiota of patients with PSC sampled
during colonoscopy and found one sole association to PSC, the
underrepresentation of an uncultured Clostridiales II.30
Expectedly, our results differ, because the transient (faecal)
microbiota differs from the adherent (mucosal) microbiota,26
and because our cohort includes patients with PSC without con-
comitant IBD and the higher sample size (N=147 vs N=32)
allows for higher discovery potential.
Elevated ALP serum levels are used in PSC diagnosis,12 as
well as in follow-up of the disease, as elevated levels reveal cho-
lestasis. Growing evidence suggests that reduced levels of ALP
are associated with an improved prognosis in PSC.31 32 In our
cohort, the genus Enterococcus positively correlated with ALP
in univariate analysis, suggesting a potential link between these
bacteria and disease severity. This was further illustrated by the
detection of species from the genus Enterococcus associated
with disease severity, using two different approaches to increase
resolution (OTU clustering and oligotyping), although this trend
will have to be conﬁrmed in a bigger cohort. Higher ALP serum
levels in patients with PSC are associated with more pronounced
cholestasis due to increasing severity in biliary strictures. Bile
colonisation by enteric bacteria such as Enterococcus spp is
more common among patients with PSC with dominant stric-
tures.33 In the study of Pohl et al, E. faecalis and E. faecium
were the most frequently isolated species in bile in patients with
PSC with dominant strictures. In the present study, we observe
an overrepresentation of the genus Enterococcus in faecal
samples, accounting for up to 2% of the faecal bacteria in
patients with PSC. It is extremely unlikely that such a high rela-
tive abundance of Enterococcus result solely from colonised bile
being discharged in the intestinal tract. Our results therefore
suggest that Enterococcus population overgrowth in the intestine
occurs, independently of the colonisation of strictured bile
ducts, in patients with PSC.
In particular, OTU1 of the genus Enterococcus was solely
responsible for the genus-level positive correlation to disease
severity. The centroid sequence of this OTU matches with
equally high percentage identity several reference bacterial
species, including E. faecalis and E. faecium. Interestingly,
E. faecalis has already been associated with impaired intestinal
permeability. Gelatinase, a metalloprotease produced by
E. faecalis, has been shown to alter the epithelial barrier, result-
ing in higher susceptibility to intestinal inﬂammation.34 The
impairment of the epithelial barrier might allow bacterial trans-
location and colonisation of the bile. Enterococcus is the most
frequently identiﬁed genus in bile culture studies, speciﬁcally
E. faecium.35
PSC frequently leads to cirrhosis, and in some cases end-stage
liver disease. Intestinal dysbiosis has already been described in
patients with liver cirrhosis, with an increase in Veillonella,
Streptococcus, Prevotella, Lactobacillus and Fusobacterium,
among others.24 E. faecalis has also been associated with liver
cirrhosis.25 In accordance with the literature, the genus
Enterococcus was overrepresented in patients with cirrhosis
from the ﬁrst cohort when compared with healthy controls. The
genus Veillonella has recently been associated with PSC.36 We
also found Streptococcus and Veillonella to be increased in
patients with PSC with liver cirrhosis; however, the association
to PSC diagnosis was no longer signiﬁcant when excluding
patients with liver cirrhosis from the analysis. At the genus level,
patients with PSC with more severe disease seem to have more
extreme deviations from healthy controls than patients with a
stable course of disease who tend to be more similar to healthy
controls. Nonetheless, no signiﬁcant differences were observed
at the genus level between patients with stable disease and
patients with either liver cirrhosis or liver transplantation.
Furthermore, the increase in Enterococcus, Fusobacterium and
Lactobacillus was also found when comparing patients with
PSC without liver cirrhosis, liver transplantation or concomitant
IBD with healthy controls.
Currently, efﬁcacious medical treatment for PSC is lacking.12
Notwithstanding, most patients with PSC are being treated with
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UDCA37 due to some evidence pointing towards possible clin-
ical beneﬁts.31 As such, around 75% of the patients with PSC in
our cohort were taking UDCA. Faecal microbiota did not differ
between patients with PSC taking UDCA and those not taking
the medication. In addition, the three genera microbial signature
is also found in patients with PSC that are not taking UDCA.
Therefore, our results are not associated with treatment with
UDCA.
Intestinal microbiota may play a role in the pathogenesis of
IBD and dysbiosis has already been described both in CD and
UC.7 Interestingly, our results are in line with previously pub-
lished data by showing a decreased α-diversity in CD while no
difference was seen in UC, and a decrease of Faecalibacterium
in CD.7 8 10 The majority of patients with PSC also have
IBD, such that PSC is considered to be an extra-intestinal
manifestation of IBD.38 The pathogenesis of PSC has not yet
been elucidated; however, mounting evidence suggests that
intestinal microbiota might also play a role in its pathogenesis.
Genome-wide association studies have already identiﬁed 16
risk loci for PSC.39 Some of these risk loci such as FUT2
are associated with increased risk of bacterial and viral infec-
tions1 and with microbiome composition.40 Furthermore,
germ-free Mdr2(−/−) mice have a more severe phenotype
of PSC.6
In conclusion, the faecal microbiota of patients with PSC
differs from that of healthy controls. A unique microbial signa-
ture of three genera was observed in patients with PSC, irre-
spective of the presence of IBD and UDCA treatment. A
positive correlation was found between the genus Enterococcus
and ALP serum levels. Our data support the hypothesis that the
intestinal microbiota plays an important role in the pathogenesis
of this chronic cholestatic liver disease.
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